Lakefront Biotherapeutics (GLPGF) Accounts Payables (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Accounts Payables for 14 consecutive years, with $112.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Accounts Payables fell 36.91% year-over-year to $112.1 million in Q1 2026; TTM through Mar 2026 was $112.1 million, a 36.91% decrease from a year earlier, with the FY2025 full-year figure at $118.2 million, up 10.48% from the prior year.
• Accounts Payables was $112.1 million for Q1 2026 at Lakefront Biotherapeutics, down from $121.8 million in the prior quarter.
• Over five years, Accounts Payables peaked at $151.7 billion in Q4 2022 and troughed at $105.7 million in Q4 2024.
• A 5-year average of $11.8 billion and a median of $145.5 million in 2023 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables tumbled 99.9% in 2023 and advanced 15.29% in 2025, its largest moves.
• Over 5 years, Accounts Payables stood at $151.7 billion in 2022, then tumbled by 99.9% to $145.5 million in 2023, then declined by 27.37% to $105.7 million in 2024, then gained by 15.29% to $121.8 million in 2025, then dropped by 7.96% to $112.1 million in 2026.
• The last three Accounts Payables figures came in at $112.1 million (Q1 2026), $121.8 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.